Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

BIOGEN INC. Director's Dealing 2025

Feb 12, 2025

30291_dirs_2025-02-12_e3c8dede-bafe-4259-bc3f-1e2f42fe82b2.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOGEN INC. (BIIB)
CIK: 0000875045
Period of Report: 2025-02-10

Reporting Person: ALEXANDER SUSAN H (EVP Chief Legal Officer)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2025-02-10 Common Stock M 2575 Acquired 37072 Direct
2025-02-10 Common Stock F 807 $142.54 Disposed 36265 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2025-02-10 Restricted Stock Unit $0 M 2575 Disposed 2025-02-10 Common Stock (2575) Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 20082 Indirect

Footnotes

F1: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 10, 2022.